Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1. Its clinical program also comprises MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to solid tumors. In addition, the company is developing preclinical product candidates for various solid tumor indications. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-441-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$144.27 million
Profitability
Miscellaneous
Employees72
OptionableOptionable
Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions
What is Merrimack Pharmaceuticals' stock symbol?
Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."
When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?
Shares of Merrimack Pharmaceuticals reverse split before market open on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were Merrimack Pharmaceuticals' earnings last quarter?
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) issued its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.28) by $0.05. View Merrimack Pharmaceuticals' Earnings History.
When is Merrimack Pharmaceuticals' next earnings date?
What price target have analysts set for MACK?
3 equities research analysts have issued 1-year price targets for Merrimack Pharmaceuticals' stock. Their forecasts range from $4.00 to $4.00. On average, they expect Merrimack Pharmaceuticals' share price to reach $4.00 in the next twelve months. This suggests that the stock has a possible downside of 31.7%. View Analyst Price Targets for Merrimack Pharmaceuticals.
What is the consensus analysts' recommendation for Merrimack Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merrimack Pharmaceuticals in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Merrimack Pharmaceuticals.
Has Merrimack Pharmaceuticals been receiving favorable news coverage?
News coverage about MACK stock has trended positive this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Merrimack Pharmaceuticals earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the near term.
Who are some of Merrimack Pharmaceuticals' key competitors?
Some companies that are related to Merrimack Pharmaceuticals include XBiotech (XBIT), American Brivision (Holding) (ABVC), Constellation Pharmaceuticals (CNST), Magenta Therapeutics (MGTA), OptiNose (OPTN), Aclaris Therapeutics (ACRS), Neptune Wellness Solutions (NEPT), Evelo Biosciences (EVLO), Adamas Pharmaceuticals (ADMS), Catalyst Pharmaceuticals (CPRX), BIOFRONTERA AG/ADR (BFRA), Minerva Neurosciences (NERV), Axsome Therapeutics (AXSM), Geron (GERN) and Intec Pharma (NTEC).
Who are Merrimack Pharmaceuticals' key executives?
Merrimack Pharmaceuticals' management team includes the folowing people:
- Dr. Richard Peters, Pres, CEO & Director (Age 56)
- Ms. Jean M. Franchi, CFO & Treasurer (Age 53)
- Mr. Jeffrey A. Munsie, Gen. Counsel, Head of Corp. Operations & Sec. (Age 42)
- Dr. Daryl C. Drummond Ph.D., Head of Research (Age 50)
- Dr. Sergio L. Santillana, Chief Medical Officer (Age 56)
Who are Merrimack Pharmaceuticals' major shareholders?
Merrimack Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include 22NW LP (5.62%), Dimensional Fund Advisors LP (4.28%), BlackRock Inc. (1.92%), Connor Clark & Lunn Investment Management Ltd. (1.27%), Two Sigma Investments LP (0.55%) and Northern Trust Corp (0.45%). Company insiders that own Merrimack Pharmaceuticals stock include Daryl C Drummond and Ulrik B Nielsen. View Institutional Ownership Trends for Merrimack Pharmaceuticals.
Which major investors are selling Merrimack Pharmaceuticals stock?
Which major investors are buying Merrimack Pharmaceuticals stock?
How do I buy shares of Merrimack Pharmaceuticals?
Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merrimack Pharmaceuticals' stock price today?
One share of MACK stock can currently be purchased for approximately $5.86.
How big of a company is Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals has a market capitalization of $78.17 million and generates $144.27 million in revenue each year. The biopharmaceutical company earns $472.02 million in net income (profit) each year or ($5.66) on an earnings per share basis. Merrimack Pharmaceuticals employs 72 workers across the globe.
What is Merrimack Pharmaceuticals' official website?
How can I contact Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]
MarketBeat Community Rating for Merrimack Pharmaceuticals (NASDAQ MACK)
MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe MACK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MACK will underperform the S&P 500 over the long term. You may vote once every thirty days.
